Dr. Mark Kieran
Who is Dr. Mark Kieran?
Mark Kieran, MD, PhD, is the Principle Investigator for Dana-Farber/Children’s Hospital Cancer Center, in partnership with the (POETIC) Pediatric Oncology Experimental Therapeutics Investigators Consortium. POETIC was founded in February 2003 by Dr. Lia Gore at the University of Colorado and Dr. Tanya Trippett at Memorial Sloan-Kettering Cancer Center. POETIC's mission is to promote the early clinical development of promising therapies for the treatment of children, adolescents and young adults with cancer and related disorders.
POETIC is composed of 11 large academic medical centers in North America with a major emphasis on comprehensive cancer care and research that provide the collaborative and research strength needed to complete intensive phase I and II studies. Each of the institutions is uniquely suited to complete early studies in the pediatric and adolescent populations.
POETIC's pediatric oncology studies focus on the biologic basis for anti-cancer therapy, and in particular, attempt to explore and evaluate new agents and novel combinations of therapies early in clinical development.
Pediatric Brain Tumor Program at Dana-Farber/Children's Hospital Cancer Center
Dr. Kieran is the Director of Pediatric Neuro-Oncology of The Pediatric Brain Tumor Program at Dana-Farber/Children's Hospital Cancer Center; the largest and most active pediatric brain tumor treatment program in New England. Their integrated program brings together pediatric neurosurgeons, neuro-oncologists, neurologists, neuropathologists, radiation oncologists, and other specialists who are entirely devoted to the treatment and research of pediatric brain tumors. This multidisciplinary team provides a unique degree of specialization which translates into advanced treatment options for young patients with newly diagnosed, relapsed or refractory brain tumors.
As one of the leading research centers for the study of pediatric brain tumors, this program offers access to: advanced technologies like the intraoperative MRI; novel antiangiogenic, biologic, and immunotherapeutic therapies; and unique treatment options through our extensive clinical trial program. In addition, long-term follow-up care is provided to young brain tumor survivors through a specialized late-effects program which helps address physical, psychological, social and intellectual challenges that may be encountered as a direct result of the disease and its treatment.